Merck’s MS treatment shows promising results

Data published in the Multiple Sclerosis Journal has shown promising results for Merck’s MS treatment Mavenclad.

An analysis was conducted of patients from the CLARITY study spanning two clinically relevant definitions of high disease activity. In both groups Mavenclad was shown to reduce the risk of 6-month EDSS progression by 82%.

Prof. Gavin Giovannoni, a lead investigator and Chair of Neurology, Barts and The London School of Medicine and Dentistry said: “This analysis provides valuable insights on the effect of Mavenclad on patients with ongoing disease activity despite treatment with platform therapy, as well as naïve patients with more relapses at baseline, who tend to do worse over time. The efficacy data presented in this publication show an even greater risk reduction on expanded disability status scale (EDSS) progression with Mavenclad in patients with highly active MS.”